Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Up – Here’s Why

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) shares gapped up prior to trading on Thursday . The stock had previously closed at $23.33, but opened at $24.45. Ascentage Pharma Group International shares last traded at $24.45, with a volume of 303 shares trading hands.

Wall Street Analyst Weigh In

AAPG has been the topic of several research analyst reports. Rodman & Renshaw started coverage on shares of Ascentage Pharma Group International in a research report on Tuesday, January 13th. They issued a “buy” rating and a $48.00 target price on the stock. Oppenheimer initiated coverage on shares of Ascentage Pharma Group International in a report on Thursday, December 4th. They issued an “outperform” rating and a $45.00 price target on the stock. BTIG Research initiated coverage on Ascentage Pharma Group International in a report on Monday, November 10th. They set a “buy” rating and a $50.00 price objective for the company. Lucid Cap Mkts raised Ascentage Pharma Group International to a “strong-buy” rating in a research report on Monday, December 15th. Finally, Truist Financial set a $51.00 price target on Ascentage Pharma Group International in a research report on Monday, November 24th. One research analyst has rated the stock with a Strong Buy rating and six have assigned a Buy rating to the company’s stock. According to MarketBeat, Ascentage Pharma Group International has an average rating of “Buy” and an average target price of $48.40.

Ascentage Pharma Group International Price Performance

The company has a current ratio of 1.54, a quick ratio of 1.53 and a debt-to-equity ratio of 1.31. The business’s 50-day moving average is $27.52 and its two-hundred day moving average is $34.26.

Institutional Investors Weigh In On Ascentage Pharma Group International

Hedge funds have recently modified their holdings of the stock. Tema Etfs LLC purchased a new position in Ascentage Pharma Group International in the 2nd quarter worth approximately $610,000. XY Capital Ltd lifted its position in shares of Ascentage Pharma Group International by 224.2% during the third quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock worth $707,000 after purchasing an additional 12,530 shares in the last quarter. UBS Group AG boosted its stake in shares of Ascentage Pharma Group International by 149.4% in the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after purchasing an additional 10,988 shares during the period. Hsbc Holdings PLC acquired a new stake in Ascentage Pharma Group International during the 2nd quarter valued at $391,000. Finally, Citadel Advisors LLC purchased a new stake in Ascentage Pharma Group International during the 3rd quarter worth $383,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.